Skip to main content
SpringerLink
Log in

Prise en charge du cancer de la jonction œso-gastrique non métastatique

  • Chapter
Post’U FMC-HGE

  • 185 Accesses

Résumé

Le cancer gastrique est un problème sanitaire mondial avec environ 930000 nouveaux cas et 700000 décès chaque année [1]. Il reste le 2e cancer digestif en France, avec environ 7000 nouveaux cas et 6000 décès par an. Son pronostic reste médiocre avec une survie relative globale à 10 ans de l’ordre de 20 % en raison d’un diagnostic tardif (notamment en Occident). Ainsi, aux États-Unis, le cancer gastrique est localisé, localement avancé, métastatique et non classé au diagnostic dans 23 %, 32 %, 33 % et 12 % des cas, respectivement, avec des taux de survie à 5 ans de 62 %, 22 %, 3 % et 13 %, respectivement. à l’inverse, au Japon, des programmes de dépistage de masse du cancer gastrique ont permis un diagnostic plus fréquemment fait à un stade précoce avec un taux de survie à 5 ans de l’ordre de 60 % [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Sasako M, Sano T, Yamamoto S et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644–51.

    Article  PubMed  Google Scholar 

  2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–9.

    Article  CAS  PubMed  Google Scholar 

  3. Corley DA, Buffler PA. OEsophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001; 30:1415–25.

    Article  CAS  PubMed  Google Scholar 

  4. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603–9.

    Article  CAS  PubMed  Google Scholar 

  5. Sant M, Aareleid T, Berrino F Faivre J et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 — results and commentary. Ann Oncol 2003; 14 (Suppl 5):v61–118.

    Article  PubMed  Google Scholar 

  6. Stein HJ, Feith M, Mueller J, Werner M, Siewert JR. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg. 2000;232:733–42.

    Article  CAS  PubMed  Google Scholar 

  7. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009;250:878–87.

    Article  PubMed  Google Scholar 

  8. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007;8: 545–53.

    Article  PubMed  Google Scholar 

  9. Mariette C, Triboulet JP. Traitement du cancer de l’oesophage. Encycl Med Chir (Elsevier, Paris) Gastroentérologie, 2004:9-205?A-30.

    Google Scholar 

  10. Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. J Chir (Paris) 2005;142:14–28.

    CAS  Google Scholar 

  11. Kelsen DP, Winter KA, Gunderson LL et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719–25.

    Article  PubMed  Google Scholar 

  12. MRC OE02 trial. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727–33.

    Article  Google Scholar 

  13. Hermanek P. pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J Surg 1995;19:184–90.

    Article  CAS  PubMed  Google Scholar 

  14. Peracchia A, Bonavina L. Outcome of surgical treatment. Adenocarcinoma of the esophagogastric junction. Milan: Edra; 2000:151–69.

    Google Scholar 

  15. Sauvanet A, Mariette C, Triboulet JP. Cancer du cardia. Rapport AFC 2003. Paris, Arnette, 2003.

    Google Scholar 

  16. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006; 15:751–64.

    Article  PubMed  Google Scholar 

  17. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol 2003;4:481–8.

    Article  PubMed  Google Scholar 

  18. Hulscher JB, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662–9.

    Article  PubMed  Google Scholar 

  19. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. OEsophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80:367–70.

    Article  CAS  PubMed  Google Scholar 

  20. Chu KM, Law SY, Fok M, Wong J. Aprospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997;174:320–4.

    Article  CAS  PubMed  Google Scholar 

  21. Jacobi CA, Zieren HU, Muller JM, Pichlmaier H. Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. Eur J Cardiothorac Surg 1997; 11:32–7.

    Article  CAS  PubMed  Google Scholar 

  22. Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? Aust N Z J Surg 1999;69:187–94.

    Article  CAS  PubMed  Google Scholar 

  23. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001;72:306–13.

    Article  CAS  PubMed  Google Scholar 

  24. Omloo JM, Lagarde SM, Hulscher JB et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992–1000; discussion-1.

    Article  PubMed  Google Scholar 

  25. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360–7; discussion 8–9.

    Article  CAS  PubMed  Google Scholar 

  26. Martin RC, 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002;236:159–65.

    Article  PubMed  Google Scholar 

  27. Thirion PG, Maillard E, Pignon J, Group2 MAoCiOCC. Individual Patient Data-based Meta-analysis Assessing the Effect of Preoperative Chemoradiotherapy in Resectable OEsophageal Carcinoma. Int J Radiat Oncol Biol Phys 2008 ASTRO Annual Meeting; 72:S71–S72.

    Google Scholar 

  28. Thirion PG, Michiels S, Le Maître A, Tierney J, Group obotMoCiECC. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. J Clin Oncol 2007 ASCO Annual Meeting. 2007; Proceedings Part I. 25:4512.

    Google Scholar 

  29. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–34.

    Article  CAS  PubMed  Google Scholar 

  30. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247:365–71.

    Article  PubMed  Google Scholar 

  31. Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet JP. Impact of preoperative radiochemo therapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg 2006;93: 1077–83.

    Article  CAS  PubMed  Google Scholar 

  32. Dexter SP, Sue-Ling H, McMahon MJ, Quirke P, Mapstone N, Martin IG. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut 2001; 48:667–70.

    Article  CAS  PubMed  Google Scholar 

  33. Slim K, Blay JY, Brouquet A et al. Digestive oncology: surgical practices. J Chir (Paris) 2009;146 (Suppl 2):S11–80.

    Google Scholar 

  34. Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 2000;36:390–6.

    Article  CAS  PubMed  Google Scholar 

  35. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88:921–32.

    Article  CAS  PubMed  Google Scholar 

  36. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999;230:170–8.

    Article  CAS  PubMed  Google Scholar 

  37. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.

    Article  CAS  PubMed  Google Scholar 

  38. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000;87:353–7.

    Article  CAS  PubMed  Google Scholar 

  39. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72:2089–97.

    Article  CAS  PubMed  Google Scholar 

  40. Mariette C, Piessen G, Vons C. [Lymphadenectomy in surgery for cancers of the stomach and esophagus]. J Chir (Paris) 2008;145 (Spec no. 4):12S21–12S29.

    Google Scholar 

  41. Hartgrink HH, van de Velde CJ, Putter H et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643–9.

    Article  CAS  PubMed  Google Scholar 

  42. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  43. Ychou M, Pignon JP, Lasser P et al. Phase III preliminary results of preoperative fluorouracil-cisplatin vs surgery alone in adenocarcinoma of stomach and lower esophagus: FNCLCC 94012-FFCD 9703 trial. Proc Am Soc Clin Oncol 2006; abstract 4026.

    Google Scholar 

  44. Ychou M, Pignon JP, Lasser P et al. Phase III final results of preoperative fluorouracil-cisplatin vs surgery alone in adenocarcinoma of stomach and lower esophagus: FNCLCC 94012-FFCD 9703 trial. Proc Am Soc Clin Oncol 2007;3:4.

    Google Scholar 

  45. Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797–805.

    Article  PubMed  Google Scholar 

  46. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305–13.

    CAS  PubMed  Google Scholar 

  47. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462–7.

    Article  CAS  PubMed  Google Scholar 

  48. Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP. Surgical management of and longtermsurvival after adenocarcinoma of the cardia. Br J Surg 2002;89:1156–63.

    Article  CAS  PubMed  Google Scholar 

  49. Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–68.

    Article  PubMed  Google Scholar 

  50. Gunderson LL. Gastric cancer — patterns of relapse after surgical resection. Semin Radiat Oncol 2002;12: 150–61.

    Article  PubMed  Google Scholar 

  51. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994;343:1309–12.

    Article  CAS  PubMed  Google Scholar 

  52. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.

    Article  CAS  PubMed  Google Scholar 

  53. Macdonald JS, Benedetti J, Smalley S et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27:1s, 2009 (suppl): abstract 4515.

    Google Scholar 

  54. Fuchs C, Tepper JE, Niedwiecki D et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Interim toxicity results from Intergroup trial CALGB 80101. ASCO Annual Meeting 2006: abstract 61.

    Google Scholar 

  55. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851–6.

    Article  CAS  PubMed  Google Scholar 

  56. Schneider BJ, Urba SG. Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care? Semin Radiat Oncol 2007;17:45–52.

    Article  PubMed  Google Scholar 

  57. Crehange G, Bonnetain F, Chauffert B et al. Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment. Cancer Radioth 2008;12:365–373.

    Article  CAS  Google Scholar 

  58. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de chirurgie digestive et générale, Hôpital C Huriez, CHRU, 59037, Lille Cedex

    C. Mariette

Authors
  1. C. Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Michel Greff Marc Barthet Laurent Beaugerie Yoram Bouhnik Jean-Pierre Bronowicki Bruno Buecher Jacques Corallo Pierre-Adrien Dalbies Franck Devulder Philippe Ducrotte Denis Grasset Jean-Paul Jacques Jean Lapuelle Philippe Levy Olivier Nouel Patrice Pienkowski Bertrand Pujol Gilbert Tucat Pascale Rouvière

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Mariette, C. (2010). Prise en charge du cancer de la jonction œso-gastrique non métastatique. In: Greff, M., et al. Post’U FMC-HGE. Springer, Paris. https://doi.org/10.1007/978-2-8178-0097-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0097-4_23

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0096-7

  • Online ISBN: 978-2-8178-0097-4

Publish with us

Policies and ethics

Search

Navigation